key: cord-0792577-as8rpq2w
authors: Helms, Julie; Severac, François; Merdji, Hamid; Anglés-Cano, Eduardo; Meziani, Ferhat
title: Prothrombotic phenotype in COVID-19 severe patients
date: 2020-05-20
journal: Intensive Care Med
DOI: 10.1007/s00134-020-06082-7
sha: 478d025377cff3a47737bd7d06e00bf67be09068
doc_id: 792577
cord_uid: as8rpq2w

nan

wards. Lung ultrasonography was thus routinely used to detect condensation or pleural effusion. We decided to perform CT-scan to (re)explore patients when ultrasonography alone could not explain blood gas deterioration. In the historical cohort of non-COVID-19 ARDS, 168 CT-scans were performed in 134 patients during their ICU stay, among which 65 were CTPA. The incidence of PE found was of 4.6% in the non-COVID ARDS cohort compared to 25% in the present COVID-19 cohort. We had the same clinical/biological arguments to ask for a CTPA in the historical cohort. Yet, only 28% of the patients required CTPA, which may have led to a potential bias of an increased detection of PE in COVID-19 patients. Finally, even if we exclude subsegmentary PE, the difference between COVID-19 and non-COVID ARDS remains statistically significant (3/233 patients, 1.3%, versus 22/150 patients, 14.7%, p < 0.001).

Our study reports a high rate of PE, in line with other studies published concomitantly. In 184 ICU patients with proven COVID-19 pneumonia, Klok et al. [3] showed that the cumulative incidence of the composite outcome including venous thromboembolism and arterial thrombotic complications was 31% (95%CI 20-41%) and that CTPA-diagnosed PE was the most frequent thrombotic complication (n = 25, 81%). Poissy et al. reported that 22/107 COVID-19 patients (20.6%) admitted in ICU were diagnosed with PE, with an absolute increase risk of 14.4% (95%CI 6.1 to 22.8%) compared to patients hospitalized in the same ICU during the same time interval in 2019 (20.6% vs 6.1%; absolute increase risk of 14.4%, 95%CI 6.1 to 22.8%) [4] . In a smaller cohort, Llitjos et al. [5] reported 6 PE in 26 patients (23%) (4 CTPA and 2 transesophageal echocardiography diagnosis). These studies are, however, difficult to compare, because the incidence of PE reported may depend on the number of CTPA performed on the global cohort. Although PE is a major thromboembolic complication in ICU, no study has systematically assessed the incidence or prevalence of this complication in ICU COVID-19 patients. Systematic CTPA screening of all patients irrespective of symptoms is the only way to assess the incidence of PE. Despite a number of limitations, our study has the strengths of being multicenter and prospective, and reporting for the first time a large number of patients. Our results are of pressing importance to better understand peculiarities of the many patients currently treated during the ongoing COVID-19 crisis worldwide. Potentially practice changes may be envisaged in terms of anticoagulation, coagulopathy profile and systematic assessment of venous thromboembolism. 

Incidence of pulmonary embolism in patients with COVID-19

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

The authors declare that they have no conflict of interest.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Accepted: 30 April 2020